Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
R-Pharm, one of Russia’s leading biotech firms, is considering expanding into the Japanese pharmaceutical market during the next several years. 4 October 2017
Russian and global pharmaceutical companies operating active substances’ production in Russia want to receive a premium of 40% of the value of the public procurements contracts signed with the Russian government, according to recent statements by Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent. 4 October 2017
While the pharmaceutical industry is often regarded as being sluggardly in its embrace of change, opportunities in digital technology appear to be on the rise, and pharma is taking notice. 3 October 2017
In an Expert View piece, Balkrishan ‘BK’ Kalra, life sciences business leader and Eric Sandor, PVAI business leader, from technology and analytics specialist Genpact, look at how artificial intelligence is making drug development safer. 3 October 2017
Dr Nicola Davies explores pharmaceutical development in mental health, with a focus on factors that influence the road to pharma-psych innovation. 3 October 2017
Privately-held Swiss drugmaker Ferring Pharmaceuticals has appointed Professor Klaus Dugi as executive vice president and chief medical officer (CMO), effective immediately. 3 October 2017
French pharma major Sanofi today announced the appointment of Stefan Oelrich as executive vice president Diabetes & Cardiovascular (DCV), effectively immediately. 2 October 2017
Science writer David Levine provides the latest quarterly Special Report piece, looking at the drug prices in one therapy area that are getting on people's nerves so much that they might prompt drastic action from the White House to bring down the cost of medicines across the board. 29 September 2017
Rare diseases had long been ignored in China until very recently. In May, China’s Food and Drug Administration (CFDA) drafted a policy to accelerate the approval process for innovative medical devices and drugs, including those for rare diseases, reports The Pharma Letter’s local correspondent Wang Fangqing. 29 September 2017
Cancer is on the rise in India. With 1 million people diagnosed with it every year, some 700,000 of them die, making it one of the leading causes of death in the country, reports The Pharma Letter’s India correspondent. 28 September 2017
The fast-changing and pressurized environment in which they operate means pharma companies must now take a more aggressive approach to adopting new leadership structures, writes Waseem Noor, a consultant at the executive search firm Russell Reynolds Associates, in an Expert View piece. 28 September 2017
Massachusetts-based Rubius Therapeutics has shaken up its executive team, with new appointments in the firm’s medical, financial, legal and HR divisions. 28 September 2017
The European Commission (EC) approval of a combination involving Kisqali (ribociclib) for a large breast cancer indication last month led a senior executive from Swiss pharma giant Novartis to proclaim that it proved the company’s ‘recognized leadership in cancer research’. 27 September 2017
Yitzhak Peterburg, Teva’s last but one CEO, recently described the pharmaceutical industry as one of the last “traditional” industries, saying it was about to undergo “huge disruption.” 27 September 2017
The share price of Ireland-incorporated drugmaker Allergan closed at $211.61 on Monday, up 3.4% for the day, after the company announced a $2 billion share buyback program and reiterated its pledge to pay down $3.75 billion of debt in 2018. 26 September 2017
Germany’s Merck KGaA (MRK: DE) has appointed Paolo Carli as head of Middle East, Africa & Turkey (MEA) region for its healthcare business. He will be responsible for leading the commercial operations for Merck across the MEA. 26 September 2017
The Russian government has prepared a bill simplifying the introduction of new drugs into the domestic pharmaceutical market, a spokesman of state press-service has said recently, reports The Pharma Letter’s local correspondent. 25 September 2017
Russian drugmaker Nanolek has reached an agreement with SK Chemicals on the establishment of production of vaccines at the facilities of the company’s Russian plant, which is located in Kirov region. 25 September 2017
Bid defenses have traditionally been considered the gold standard for culminating the contract research organization (CRO) selection process, writes Laurie Halloran, president and chief executive of Halloran Consulting Group, in an Expert View piece giving her perspective on how both parties can make the most out of this process. 21 September 2017
A fruitful congress of the European Society of Medical Oncology last week provided key insights into melanoma, lung, kidney and ovarian cancer research. 19 September 2017